Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 4 November 2026.
Announcements
6,261
Total raised
£165B
disclosed amounts
This month
£10.5M
raised so far
The funding round was led by Technology Venture Partners alongside government backing to support the commercialisation of a new breast scanning system.
"this investment will allow us to move the company into the next phase with a system that has a place in a clinical workflow and more exciting functionality to come as soon as clinical data collection can re commence"
The fire and electrical compliance provider completed its primary buyout led by YFM Equity Partners.
"Over the last 30 years, RGE Services has established a solid reputation as a supplier which is trusted by public sector organisations. We understand the high levels of customer service they need in order to ensure that all types of electrical, fire and security projects are safe for users, and also to enable them to demonstrate that a robust compliance procedure has been followed."
The biotechnology company has obtained grant funding to advance its antibacterial therapy through Phase 1 clinical trials.
"To receive funding from CARB-X is important validation for our SASPject technology platform and its potential in fighting bacterial resistance. It has been awarded at the end of a thorough due diligence process which reinforces the credibility of the company and our team – I am delighted to now look forward to progressing our lead product to clinical trials and developing a product pipeline that will advance the science of antibacterial therapy and in time, save millions of lives round the world."
Koch Disruptive Technologies led the Series B round to support the commercialisation of the Veros diagnostics platform.
"This Series B round is crucial in providing us with the resources to grow our Veros platform to revolutionize decentralized point-of-care testing; and it is particularly important as we commercialize our Veros COVID-19 test, which delivers laboratory quality results directly to users within minutes, without an instrument. This will be an essential tool in the effective management of outbreaks of this and other diseases,"
Cambridge Enterprise led the seed financing, which includes backing from Parkwalk, New Grounds, and R42 Group.
"Many researchers would like to get molecular binding data more conveniently and more frequently to guide them through a drug development project. HexagonFab aims to address this need with the Bolt. This investment will enable us to bring our game-changing product to the market. We look forward to the months ahead working closely with our lead customers,"
